{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:55:16Z","timestamp":1780466116862,"version":"3.54.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.jneuroim.2015.02.010","type":"journal-article","created":{"date-parts":[[2015,3,2]],"date-time":"2015-03-02T23:50:57Z","timestamp":1425340257000},"page":"61-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Low and high doses of ursolic acid ameliorate experimental autoimmune myasthenia gravis through different pathways"],"prefix":"10.1016","volume":"281","author":[{"given":"Hua","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-Tao","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong-Cong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Sheng","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2015.02.010_bb0005","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.phrs.2005.11.005","article-title":"Amelioration of adjuvant-induced arthritis by ursolic acid through altered Th1\/Th2 cytokine production","volume":"53","author":"Ahmad","year":"2006","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0010","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.cellimm.2011.07.007","article-title":"Characterization of peripheral blood acetylcholine receptor-binding B cells in experimental myasthenia gravis","volume":"271","author":"Allman","year":"2011","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0015","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2567.2006.02398.x","article-title":"A dual altered peptide ligand down-regulates myasthenogenic T cell responses and reverses experimental autoimmune myasthenia gravis via up-regulation of Fas\u2013FasL-mediated apoptosis","volume":"118","author":"Aruna","year":"2006","journal-title":"Immunology"},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0020","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.4049\/jimmunol.172.4.2697","article-title":"Breakdown of tolerance to a self-peptide of acetylcholine receptor alpha-subunit induces experimental myasthenia gravis in rats","volume":"172","author":"Baggi","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0025","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in myasthenia gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0030","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1006\/clim.1999.4807","article-title":"Animal models of myasthenia gravis","volume":"94","author":"Christadoss","year":"2000","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0035","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1085-9489.2006.00063.x","article-title":"Fas-mediated T-cell apoptosis is impaired in patients with chronic inflammatory demyelinating polyneuropathy","volume":"11","author":"Comi","year":"2006","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0040","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1212\/WNL.55.7.921","article-title":"Defective T cell Fas function in patients with multiple sclerosis","volume":"55","author":"Comi","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0045","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0050","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1196\/annals.1405.042","article-title":"CD4+ T cells and cytokines in the pathogenesis of acquired myasthenia gravis","volume":"1132","author":"Conti-Fine","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0055","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jaut.2013.12.013","article-title":"Innate immunity in myasthenia gravis thymus: pathogenic effects of toll-like receptor 4 signaling on autoimmunity","volume":"52","author":"Cordiglieri","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0060","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199406233302507","article-title":"Myasthenia gravis","volume":"330","author":"Drachman","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0065","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0952-7915(00)00160-6","article-title":"Helper T cells in antibody-mediated, organ-specific autoimmunity","volume":"12","author":"Elson","year":"2000","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0070","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1749-6632.2012.06791.x","article-title":"Defects of immunoregulatory mechanisms in myasthenia gravis: role of IL-17","volume":"1274","author":"Gradolatto","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0075","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jaut.2013.12.015","article-title":"Both Treg cells and Tconv cells are defective in the Myasthenia gravis thymus: Roles of IL-17 and TNF-alpha","volume":"52","author":"Gradolatto","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0080","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1084\/jem.181.2.547","article-title":"Myasthenia gravis-like syndrome induced by expression of interferon gamma in the neuromuscular junction","volume":"181","author":"Gu","year":"1995","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0085","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/ni1254","article-title":"Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages","volume":"6","author":"Harrington","year":"2005","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0090","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.autrev.2010.07.003","article-title":"Interleukin-17-producing T helper cells in autoimmunity","volume":"9","author":"Hemdan","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0095","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1749-6632.1987.tb51321.x","article-title":"Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis","volume":"505","author":"Howard","year":"1987","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"6805","key":"10.1016\/j.jneuroim.2015.02.010_bb0100","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/35037728","article-title":"CD95's deadly mission in the immune system","volume":"407","author":"Krammer","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0105","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/74994","article-title":"Mitochondrial control of cell death","volume":"6","author":"Kroemer","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0110","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.foodchem.2013.04.044","article-title":"Anti-inflammatory effects of 27 selected terpenoid compounds tested through modulating Th1\/Th2 cytokine secretion profiles using murine primary splenocytes","volume":"141","author":"Ku","year":"2013","journal-title":"Food Chem."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0115","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S1568-9972(02)00146-5","article-title":"Autoantibodies to ion channels at the neuromuscular junction","volume":"2","author":"Lang","year":"2003","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0120","doi-asserted-by":"crossref","first-page":"E294","DOI":"10.25011\/cim.v35i5.18702","article-title":"Up-regulated expression of Fas antigen in peripheral T cell subsets in patients with myasthenia gravis","volume":"35","author":"Mai","year":"2012","journal-title":"Clin. Invest. Med."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0125","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1111\/j.1476-5381.2012.01869.x","article-title":"Natural triterpenes modulate immune-inflammatory markers of experimental autoimmune encephalomyelitis: therapeutic implications for multiple sclerosis","volume":"166","author":"Martin","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0130","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jneuroim.2010.03.016","article-title":"Clinical implication of peripheral CD4+CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients","volume":"225","author":"Masuda","year":"2010","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0135","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.autrev.2011.05.004","article-title":"Human Foxp3+ regulatory T cells in systemic autoimmune diseases","volume":"10","author":"Miyara","year":"2011","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0140","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2567.2009.03089.x","article-title":"Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis","volume":"128","author":"Mu","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0145","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0092-8674(00)81874-7","article-title":"Apoptosis by death factor","volume":"88","author":"Nagata","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0150","doi-asserted-by":"crossref","first-page":"12642","DOI":"10.1073\/pnas.221456798","article-title":"The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes","volume":"98","author":"Paas-Rozner","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0155","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0952-7915(98)80222-7","article-title":"Mechanisms of CD95 (APO-1\/Fas)-mediated apoptosis","volume":"10","author":"Peter","year":"1998","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0160","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0165-5728(00)00385-4","article-title":"Suppression of experimental autoimmune myasthenia gravis in IL-10 gene-disrupted mice is associated with reduced B cells and serum cytotoxicity on mouse cell line expressing AChR","volume":"111","author":"Poussin","year":"2000","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0165","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1078\/094471103322331421","article-title":"Effect of naturally occurring triterpenoids glycyrrhizic acid, ursolic acid, oleanolic acid and nomilin on the immune system","volume":"10","author":"Raphael","year":"2003","journal-title":"Phytomedicine"},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0170","first-page":"936","article-title":"T lymphocyte apoptosis in systemic lupus erythematosus patients","volume":"16","author":"Rastin","year":"2013","journal-title":"Iran. J. Basic Med. Sci."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0175","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/mus.22070","article-title":"Increased serum interleukin-17 levels in patients with myasthenia gravis","volume":"44","author":"Roche","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0180","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.0105-2896.2006.00427.x","article-title":"Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease","volume":"212","author":"Sakaguchi","year":"2006","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0185","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/187152312803476264","article-title":"Naturally occurring and synthetic agents as potential anti-inflammatory and immunomodulants","volume":"11","author":"Sultana","year":"2012","journal-title":"Anti-Inflammatory Anti-Allergy Agents Med. Chem."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0190","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jaut.2013.12.014","article-title":"Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis","volume":"52","author":"Thiruppathi","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0195","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJM197701202960301","article-title":"Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice","volume":"296","author":"Toyka","year":"1977","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0200","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.4049\/jimmunol.171.7.3847","article-title":"Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis","volume":"171","author":"Tuzun","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0205","doi-asserted-by":"crossref","first-page":"5743","DOI":"10.4049\/jimmunol.172.9.5743","article-title":"Circulating immune complexes augment severity of antibody-mediated myasthenia gravis in hypogammaglobulinemic RIIIS\/J mice","volume":"172","author":"Tuzun","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0210","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/nri916","article-title":"Unravelling the pathogenesis of myasthenia gravis","volume":"2","author":"Vincent","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0404.2006.00605.x","article-title":"Immunology of disorders of neuromuscular transmission","volume":"183","author":"Vincent","year":"2006","journal-title":"Acta Neurol. Scand. Suppl."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0220","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1006\/clim.2000.4850","article-title":"Role for interferon-gamma in rat strains with different susceptibility to experimental autoimmune myasthenia gravis","volume":"95","author":"Wang","year":"2000","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0225","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/eji.201242679","article-title":"Astrocytic Fas ligand expression is required to induce T-cell apoptosis and recovery from experimental autoimmune encephalomyelitis","volume":"43","author":"Wang","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0230","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1365-3083.2012.02703.x","article-title":"T helper type 17 cells expand in patients with myasthenia-associated thymoma","volume":"76","author":"Wang","year":"2012","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0235","doi-asserted-by":"crossref","first-page":"22707","DOI":"10.1074\/jbc.C111.250407","article-title":"Ursolic acid suppresses interleukin-17 (IL-17) production by selectively antagonizing the function of RORgamma t protein","volume":"286","author":"Xu","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0240","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0165-5728(00)00411-2","article-title":"Interleukin 10 aggravates experimental autoimmune myasthenia gravis through inducing Th2 and B cell responses to AChR","volume":"113","author":"Zhang","year":"2001","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0245","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.molimm.2008.08.274","article-title":"Dendritic cells transduced with lentiviral-mediated RelB-specific ShRNAs inhibit the development of experimental autoimmune myasthenia gravis","volume":"46","author":"Zhang","year":"2009","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0250","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jneuroim.2006.04.011","article-title":"Intravenous immunoglobulin suppresses experimental myasthenia gravis: immunological mechanisms","volume":"176","author":"Zhu","year":"2006","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2015.02.010_bb0255","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/eji.200939914","article-title":"Ectopic GC in the thymus of myasthenia gravis patients show characteristics of normal GC","volume":"40","author":"Zuckerman","year":"2010","journal-title":"Eur. J. Immunol."}],"updated-by":[{"DOI":"10.1016\/j.jneuroim.2019.03.016","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T00:00:00Z","timestamp":1557878400000}}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572815000430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572815000430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T10:15:57Z","timestamp":1566382557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572815000430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":51,"alternative-id":["S0165572815000430"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2015.02.010","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.jneuroim.2019.03.016","asserted-by":"object"}]},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low and high doses of ursolic acid ameliorate experimental autoimmune myasthenia gravis through different pathways","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2015.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}